NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
Clinical Trials
10 trialsNCT02721732 2026-01-29
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04926181 2025-05-15
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT00412880 2022-06-22
BI 2536 Second Line Monotherapy in SCLC
Boehringer Ingelheim
Phase 2 Completed
NCT01470248 2021-02-17
Study of Arsenic Trioxide in Small Cell Lung Cancer
Emory University
Phase 2 Completed
NCT00298896 2018-07-26
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Sunesis Pharmaceuticals
Phase 2 Completed
NCT00129974 2017-06-16
Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
Tufts Medical Center
Phase 2 Terminated
NCT00284154 2013-03-13
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00305942 2013-01-31
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed